FELIQS Secures $9 Million in Series A Funding to Advance Treatment for Retinopathy of Prematurity
FELIQS Corporation's $9 million Series A funding will accelerate the clinical development of FLQ-101, a promising treatment for retinopathy of prematurity, addressing a critical unmet need in neonatal care.
